CALT News and Press, Calliditas Therapeutics AB From 08/09/21

The FDA has granted Fast Track Designation to Calliditas Therapeutics' (NASDAQ:CALT) lead NOX inhibitor candidate setanaxib for the treatment of patients with the chronic orphan liver disease primary biliary cholangitis (PBC). Fast Track status provides for more frequent interaction with the ...

Calliditas Receives FDA Fast Track Designation for setanaxib in PBC PR Newswire STOCKHOLM , Aug. 9, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the U.S. Food and Drug Administr...

Calliditas Therapeutics and STADA partner to register and commercialize specialty therapy for IgA Nephropathy in Europe Calliditas and STADA partner to bring a specialty therapy focused on downregulating IgA1 to European patients. If approved, it would be the first-ever approved...

Calliditas secures $75 million term loan facility PR Newswire STOCKHOLM , July 15, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the company has signed a loan agreement of up to the ...

Calliditas Therapeutics (CALT) announces that the company submitted a Marketing Authorisation Application ((MAA)) to the European Medicines Agency ((EMA)) for nefecon, a novel oral formulation targeting down regulation of IgA1 for the treatment of primary IgA Nephropathy ((IgAN)), a form of k...

Calliditas Announces Submission of Marketing Authorisation Application for Nefecon to the European Medicines Agency PR Newswire STOCKHOLM , May 28, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today...

Calliditas Therapeutics to Present at Jefferies Virtual Healthcare Conference PR Newswire STOCKHOLM , May 28, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") today announced that management will present at the Jefferies Virtual Healthcare ...

Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ) PR Newswire STOCKHOLM , May 27, 2021 /PRNewswire/ -- The following resolutions were passed at Calliditas Therapeutics AB (publ) ("Calliditas") annual general meeting held today, on ...

Calliditas Therapeutics AB (CALT) Q1 2021 Earnings Conference Call May 18, 2021 08:30 AM ET Company Participants Renée Lucander - CEO Richard Philipson - Chief Medical Officer Fredrik Johansson - CFO Andrew Udell - President, North America Conference Call Participants Yigal Nochomovitz -...

The following slide deck was published by Calliditas Therapeutics AB (publ) in conjunction with their 2021 Q1 earnings call. For further details see: Calliditas Therapeutics AB (publ) 2021 Q1 - Results - Earnings Call Presentation